| Literature DB >> 31263278 |
Qingkun Liu1, Emily M Johnson1,2, Rachel K Lam3, Qian Wang1, Hong Bo Ye1, Edward N Wilson1, Paras S Minhas1, Ling Liu4,5, Michelle S Swarovski1, Stephanie Tran1, Jing Wang1, Swapnil S Mehta1, Xi Yang6, Joshua D Rabinowitz4,5, Samuel S Yang6, Mehrdad Shamloo3, Christoph Mueller7, Michelle L James1,2,8, Katrin I Andreasson9,10,11.
Abstract
Stroke is a multiphasic process in which initial cerebral ischemia is followed by secondary injury from immune responses to ischemic brain components. Here we demonstrate that peripheral CD11b+CD45+ myeloid cells magnify stroke injury via activation of triggering receptor expressed on myeloid cells 1 (TREM1), an amplifier of proinflammatory innate immune responses. TREM1 was induced within hours after stroke peripherally in CD11b+CD45+ cells trafficking to ischemic brain. TREM1 inhibition genetically or pharmacologically improved outcome via protective antioxidant and anti-inflammatory mechanisms. Positron electron tomography imaging using radiolabeled antibody recognizing TREM1 revealed elevated TREM1 expression in spleen and, unexpectedly, in intestine. In the lamina propria, noradrenergic-dependent increases in gut permeability induced TREM1 on inflammatory Ly6C+MHCII+ macrophages, further increasing epithelial permeability and facilitating bacterial translocation across the gut barrier. Thus, following stroke, peripheral TREM1 induction amplifies proinflammatory responses to both brain-derived and intestinal-derived immunogenic components. Critically, targeting this specific innate immune pathway reduces cerebral injury.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31263278 PMCID: PMC6778967 DOI: 10.1038/s41590-019-0421-2
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 25.606